RT Journal Article
SR Electronic
T1 Introductions and early spread of SARS-CoV-2 in the New York City area
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.08.20056929
DO 10.1101/2020.04.08.20056929
A1 Ana S. Gonzalez-Reiche
A1 Matthew M. Hernandez
A1 Mitchell Sullivan
A1 Brianne Ciferri
A1 Hala Alshammary
A1 Ajay Obla
A1 Shelcie Fabre
A1 Giulio Kleiner
A1 Jose Polanco
A1 Zenab Khan
A1 Bremy Alburquerque
A1 Adriana van de Guchte
A1 Jayeeta Dutta
A1 Nancy Francoeur
A1 Betsaida Salom Melo
A1 Irina Oussenko
A1 Gintaras Deikus
A1 Juan Soto
A1 Shwetha Hara Sridhar
A1 Ying-Chih Wang
A1 Kathryn Twyman
A1 Andrew Kasarskis
A1 Deena Rose Altman
A1 Melissa Smith
A1 Robert Sebra
A1 Judith Aberg
A1 Florian Krammer
A1 Adolfo García-Sastre
A1 Marta Luksza
A1 Gopi Patel
A1 Alberto Paniz-Mondolfi
A1 Melissa Gitman
A1 Emilia Mia Sordillo
A1 Viviana Simon
A1 Harm van Bakel
YR 2020
UL http://medrxiv.org/content/early/2020/04/16/2020.04.08.20056929.abstract
AB New York City (NYC) has emerged as one of the epicenters of the current SARS-CoV2 pandemic. To identify the early events underlying the rapid spread of the virus in the NYC metropolitan area, we sequenced the virus causing COVID19 in patients seeking care at the Mount Sinai Health System. Phylogenetic analysis of 84 distinct SARS-CoV2 genomes indicates multiple, independent but isolated introductions mainly from Europe and other parts of the United States. Moreover, we find evidence for community transmission of SARS-CoV2 as suggested by clusters of related viruses found in patients living in different neighborhoods of the city.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under award numbers S10OD018522 and S10OD026880 as well as institutional funds. Protocols established for this study were in part based on influenza virus sequencing protocols established with the support of CRIP (Center for Research on Influenza Pathogenesis), an NIH funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract number HHSN272201400008C). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome sequencing data for all study isolates has been deposited in GISAID. https://www.gisaid.org/